Source:http://linkedlifedata.com/resource/pubmed/id/18480054
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
27
|
pubmed:dateCreated |
2008-6-30
|
pubmed:abstractText |
The potassium channel Kv1.3 is an attractive pharmacological target for immunomodulation of T cell-mediated autoimmune diseases. Potent and selective blockers of Kv1.3 are potential therapeutics for treating these diseases. Here we describe the design of a new peptide inhibitor that is potent and selective for Kv1.3. Three residues (Gly(11), Ile(28), and Asp(33)) of a scorpion toxin BmKTX were substituted by Arg(11), Thr(28), and His(33), resulting in a new peptide, named ADWX-1. The ADWX-1 peptide blocked Kv1.3 with picomolar affinity (IC(50), 1.89 pM), showing a 100-fold increase in activity compared with the native BmKTX toxin. The ADWX-1 also displayed good selectivity on Kv1.3 over related Kv1.1 and Kv1.2 channels. Furthermore, alanine-scanning mutagenesis was carried out to map the functional residues of ADWX-1 in blocking Kv1.3. Moreover, computational simulation was used to build a structural model of the ADWX-1-Kv1.3 complex. This model suggests that all mutated residues are favorable for both the high potency and selectivity of ADWX-1 toward Kv1.3. While Arg(11) of ADWX-1 interacts with Asp(386) in Kv1.3, Thr(28) and His(33) of ADWX-1 locate right above the selectivity filter-S6 linker of Kv1.3. Together, our data indicate that the specific ADWX-1 peptide would be a viable lead in the therapy of T cell-mediated autoimmune diseases, and the successful design of ADWX-1 suggests that rational design based on the structural model of the peptide-channel complex should accelerate the development of diagnostic and therapeutic agents for human channelopathies.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Kv1.1 Potassium Channel,
http://linkedlifedata.com/resource/pubmed/chemical/Kv1.2 Potassium Channel,
http://linkedlifedata.com/resource/pubmed/chemical/Kv1.3 Potassium Channel,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides,
http://linkedlifedata.com/resource/pubmed/chemical/Potassium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Scorpion Venoms
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
4
|
pubmed:volume |
283
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
19058-65
|
pubmed:meshHeading |
pubmed-meshheading:18480054-Animals,
pubmed-meshheading:18480054-Autoimmune Diseases,
pubmed-meshheading:18480054-Drug Design,
pubmed-meshheading:18480054-Humans,
pubmed-meshheading:18480054-Immunity, Cellular,
pubmed-meshheading:18480054-Kv1.1 Potassium Channel,
pubmed-meshheading:18480054-Kv1.2 Potassium Channel,
pubmed-meshheading:18480054-Kv1.3 Potassium Channel,
pubmed-meshheading:18480054-Mice,
pubmed-meshheading:18480054-Models, Molecular,
pubmed-meshheading:18480054-Peptide Mapping,
pubmed-meshheading:18480054-Peptides,
pubmed-meshheading:18480054-Potassium Channel Blockers,
pubmed-meshheading:18480054-Protein Binding,
pubmed-meshheading:18480054-Protein Structure, Secondary,
pubmed-meshheading:18480054-Scorpion Venoms,
pubmed-meshheading:18480054-T-Lymphocytes
|
pubmed:year |
2008
|
pubmed:articleTitle |
Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
|
pubmed:affiliation |
State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|